Risankizumab versus ustekinumab for plaque psoriasis: a critical appraisal.
CONCLUSIONS: Gordon et al conclude that risankizumab has a higher efficacy than placebo and ustekinumab in the treatment of moderate-to-severe chronic plaque psoriasis, and that the adverse event profiles were similar across all treatment groups. This article is protected by copyright. All rights reserved.
PMID: 30632140 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Al-Janabi A, Jabbar-Lopez ZK, Griffiths CEM, Yiu ZZN Tags: Br J Dermatol Source Type: research
More News: Australia Health | Austria Health | Belgium Health | Canada Health | Czechia Health | Dermatology | France Health | Germany Health | Japan Health | Mexico Health | Poland Health | Portugal Health | Psoriasis | Skin | South Korea Health | Spain Health | Stelara | Study | UK Health